By Stephen Nakrosis 
 

AstraZeneca PLC (AZN) and Merck & Co. Inc. (MRK) on Monday said trial results for Lynparza showed "a statistically significant and clinically meaningful" improvement in radiographic progression-free survival for certain patients with prostate cancer.

Lynparza, or olaparib, also reduced the risk of the disease's progression on death in 51% of patients who had a homologous recombination repair gene mutation, the companies said.

The Phase III PROfound trial involved 387 men with metastatic castration-resistant prostate cancer who also had a mutation in their homologous recombination repair, or HRR, gene, the companies said.

Results showed the test met the primary endpoint of radiographic progression-free survival, "reducing the risk of disease progression or death by a median of 7.4 months versus 3.6 months for those receiving abiraterone or enzalutamide," the companies said.

The trial also met the key secondary endpoint of radiographic progression-free survival in those with HRR mutations, with Lynparza reducing the risk of disease progression or death by 51%. It also improved radiographic progression-free survival to a median of 5.8 months against the 3.5 months for those receiving abiraterone or enzalutamide, the companies said.

Results were presented at the European Society of Medical Oncology congress in Barcelona.

 

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

 

(END) Dow Jones Newswires

September 30, 2019 12:04 ET (16:04 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Jul 2020 to Aug 2020 Click Here for more Astrazeneca Charts.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Aug 2019 to Aug 2020 Click Here for more Astrazeneca Charts.